**Extended release topical ointment for *Tritrichomonas foetus* in bulls**

*Auburn University is seeking a licensee or development partner for a topical treatment for *Tritrichomonas foetus*.*

**Overview:** Auburn University is seeking a licensee or development partner for an extended release topical ointment for treating *Tritrichomonas foetus* (*T. foetus*) infection in bulls. Although a vaccine for female cattle exists, there is not a vaccine or FDA-approved treatment for *T. foetus* in bulls.

**Advantages:**
- **COST SAVING** - Provides an alternative to culling infected prize bulls and reduces occurrence of *T. foetus*-induced abortions
- **PREVENTATIVE** - Regular application with proper herd management could prevent or eliminate *T. foetus* in bulls, prevent spread to cows, and eliminate *T. foetus* in the herd.
- **EASILY APPLIED** - Topical application is simple and quick

**Description:** The prevalence of *T. foetus* at the herd level is anywhere from 10-40% with larger herds being most affected. Infection in females can lead to embryonic death and abortion, a significant financial loss to the farmer. The total economic impact of *T. foetus* is not well known, but assuming a 5% loss of calves due to *T. foetus* infection it is estimated that losses over $1B are seen annually in the US. A vaccine exists for females but there is no FDA-approved treatment available for bulls. Because infected bulls can spread *T. foetus* throughout a herd, once they are identified as infected they are usually slaughtered - a significant loss to the farmer of up to $100,000 or more for prized bulls. This gel-based formulation would allow topical treatment of infected bulls and avoid culling of *T. foetus* positive animals. Efficacy *in vitro* using benzimidazoles and ponazuril antimicrobials has been demonstrated. Studies in live bulls are pending to determine whether one or more applications will be needed.

**Status:**
- Subject of US Patent application (20180326072)
- Formulations demonstrated *in vitro*; studies in bulls are ongoing
- This technology is available for exclusive or non-exclusive licensing

**Inventor:**

*Dr. Sue Duran*
Professor
Dept. of Clinical Sciences

**Contact:**

Troy Brady
Auburn University
Innovation Advancement & Commercialization
334-844-4977
lifesci@auburn.edu
iac.auburn.edu
Reference: *T foetus* treatment

**Additional Available Technologies:**
- Life Sciences
- Physical Sciences

**This is Innovation. This is Auburn.**

Auburn University is an equal opportunity educational institution employer.